Dianne C. Whitfield, Chief Human Assets Officer at Tarsus Prescribed drugs (NASDAQ:TARS), reported the direct sale of 12,274 shares of widespread inventory in a number of open-market transactions between March 17 and March 19, 2026, as disclosed within the SEC Type 4 submitting.
|
Metric |
Worth |
|---|---|
|
Shares bought (direct) |
12,274 |
|
Transaction worth |
~$839,000 |
|
Submit-transaction widespread shares (direct) |
35,028 |
|
Submit-transaction worth (direct possession) |
~$2.34 million |
Transaction worth primarily based on SEC Type 4 weighted common buy worth ($68.36); post-transaction worth primarily based on trade-date shut worth as per SEC Type 4 submitting.
-
How does this sale examine to Whitfield’s prior insider transactions at Tarsus Prescribed drugs?
The 12,274 shares bought exceeded the median insider sale of 9,835 shares over the previous yr, although it’s consistent with her latest sample of decreasing holdings in increments that replicate obtainable share capability. -
What quantity of her total place did Whitfield cut back on this transaction?
This sale represented 25.95% of her direct holdings on the time, as reported within the submitting, bringing her direct share depend from 47,302 to 35,028. -
Was this transaction related to any oblique entities or spinoff workouts?
All shares traded had been held straight by Whitfield; there have been no gross sales from trusts, LLCs, or by way of spinoff safety workouts. -
What’s the context for timing and market pricing of those gross sales?
The weighted common sale worth was round $68.36 per share, in comparison with a closing worth of $66.75 on March 19, 2026; over the previous yr, Tarsus Prescribed drugs shares had a complete return of twenty-two.48% as of the transaction date.
|
Metric |
Worth |
|---|---|
|
Worth (as of market shut 3/19/26) |
$68.36 |
|
Market capitalization |
$2.73 billion |
|
Income (TTM) |
$451.36 million |
|
Internet earnings (TTM) |
-$66.42 million |
* 1-year efficiency is calculated utilizing March nineteenth, 2026 because the reference date.
-
Tarsus Prescribed drugs develops and commercializes novel therapeutics for ophthalmic and different ailments, with its lead product TP-03 concentrating on Demodex blepharitis and meibomian gland illness; further pipeline property embrace TP-04 for rosacea and TP-05 for Lyme prophylaxis and malaria discount.
-
Tarsus targets ophthalmologists, dermatologists, and healthcare suppliers treating eye and pores and skin ailments, with a give attention to sufferers affected by Demodex-related circumstances and different underserved indications.
Tarsus Prescribed drugs operates on the intersection of biotechnology and ophthalmology, specializing in unmet medical wants in eye care and associated fields. The corporate’s technique facilities on advancing first-in-class therapeutics by way of late-stage medical improvement and commercialization. Its aggressive edge lies in a differentiated pipeline addressing high-prevalence circumstances with restricted therapy choices, supported by a specialised industrial infrastructure.
